A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

ClinicalTrials.gov ID: NCT02570308

Public ClinicalTrials.gov record NCT02570308. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma

Study identification

NCT ID: NCT02570308
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Immunocore Ltd; Industry
Enrollment: 146 participants

Conditions and interventions

Conditions

Uveal Melanoma

Interventions

IMCgp100 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 28, 2016
Primary completion: Mar 19, 2020
Completion: Oct 16, 2022
Last update posted: Mar 20, 2023

2016 – 2022

United States locations

U.S. sites: 17
U.S. states: 12
U.S. cities: 16

Facility	City	State	ZIP	Site status
University California, San Diego Moores Cancer Center	La Jolla	California	92093	—
The Angeles Clinic and Research Institute - W LA Office	Los Angeles	California	90025	—
California Pacific Medical Center	San Francisco	California	94115	—
University of Colorado Denver Anschutz Medical Campus	Aurora	Colorado	80045	—
Georgetown University - Lombardi Comprehensive Cancer Center	Washington D.C.	District of Columbia	20007	—
University of Miami Hospital Clinics/Sylvester Comprehensive Cancer Center	Miami	Florida	33136	—
H. Lee Moffitt Cancer Center and Research Institute, Inc	Tampa	Florida	33612-9497	—
The University of Chicago Medical Center	Chicago	Illinois	60637	—
Washington University, School of Medicine	St Louis	Missouri	63110	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
Columbia University Medical Center - The New York Presbyterian Hospital	New York	New York	10032	—
Memorial Sloan Kettering Hospital	New York	New York	10065	—
Dean A. Mcgee Eye Institute	Oklahoma City	Oklahoma	73104	—
Providence Portland Medical Center	Portland	Oregon	97213	—
Thomas Jefferson University Medical Oncology Clinic	Philadelphia	Pennsylvania	19107	—
Vanderbilt University Medical Center	Nashville	Tennessee	37232	—
Baylor Scott & White Health	Temple	Texas	76508	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02570308, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 20, 2023 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02570308 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →